What if there were no new antibiotics? A look at alternatives

Expert Review of Clinical Pharmacology

Volumn 9, Issue 12, 2016, Pages 1547-1555

  Rello, Jordi ^a   Bunsow, Eleonora ^b   Perez, Antonio ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

antimicrobial agents; bacteriophages; liposomes; Monoclonal antibodies; stem cells; vaccines

Indexed keywords

ANTIBIOTIC AGENT; ASN 100; LIPOSOME; MEDI 3902; MEDI 4893; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VACCINE; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIOPHAGE; DRUG APPROVAL; DRUG COST; DRUG RESEARCH; HOSPITAL INFECTION; HUMAN; MESENCHYMAL STEM CELL; MULTIDRUG RESISTANCE; NONHUMAN; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; ANIMAL; BACTERIAL INFECTIONS; BACTERIUM; DRUG EFFECTS; ECONOMICS; LEGISLATION AND JURISPRUDENCE; MICROBIOLOGY;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; DRUG APPROVAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS;

EID: 84990219147     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1080/17512433.2016.1241141     Document Type: Article

References (63)

1. Opal SM., The evolution of the understanding of sepsis, infection, and the host response:a brief history. Crit Care Clin. 2009;25(4):637–63, vii.
2. Woolhouse M, Page RL, Jensen WA, et al. Antimicrobial resistance in humans, livestock and the wider environment. Philos Trans R Soc Lond B Biol Sci. 2015;370(1670):20140083.
3. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria:an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–281.
4. Kollef MH, Fraser VJ. Antibiotic resistance in the intensive care unit. Ann Intern Med. 2001;134(4):298–314.
5. Kaye KS, Engemann JJ, Fraimow HS, et al. Pathogens resistant to antimicrobial agents:epidemiology, molecular mechanisms, and clinical management. Infect Dis Clin North Am. 2004;18(3):467–511, viii.
6. Prevention, C.f.D.C.a., Antibiotic resistance threats in the United States, 2013. 2014. [cited 2016 July 8]. Available from:http://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf.
7. O’Neill J, Tackling Drug-Resistant Infections Globally:final Report And recommendations. Review on Antimicrobial Resistance, May 2016.
8. Payne DJ, Gwynn MN, Holmes DJ, et al. Drugs for bad bugs:confronting the challenges of antibacterial discovery. Nat Rev Drug Discov. 2007;6(1):29–40.
9. Hay M, Thomas DW, Craighead JL, et al. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014;32(1):40–51.
10. Cooper MA, Shlaes D. Fix the antibiotics pipeline. Nature. 2011;472(7341):32.
11. Priya Sharma AT, New drugs to tackle antimicrobial resistance:analysis of EU policy options. 2010. [cited 2016 Sep 28]. Available from:https://www.ohe.org/publications/new-drugs-tackle-antimicrobial-resistance-eu-policy-options
12. Harbarth S, Theuretzbacher U, Hackett J. Antibiotic research and development:business as usual? J Antimicrob Chemother. 2015;70(6):1604–1607.
13. Boucher HW, Talbot GH, Benjamin DK, et al. 10 x ‘20 Progress–development of new drugs active against gram-negative bacilli:an update from the infectious diseases society of America. Clin Infect Dis. 2013;56(12):1685–1694.
14. Bax R, Green S. Antibiotics:the changing regulatory and pharmaceutical industry paradigm. J Antimicrob Chemother. 2015;70(5):1281–1284.
15. Lewis K. Antibiotics:recover the lost art of drug discovery. Nature. 2012;485(7399):439–440.
16. Silver LL. Challenges of antibacterial discovery. Clin Microbiol Rev. 2011;24(1):71–109.
17. Pucci MJ, Bush K. Investigational antimicrobial agents of 2013. Clin Microbiol Rev. 2013;26(4):792–821.
18. Bassetti M, Merelli M, Temperoni C, et al. New antibiotics for bad bugs:where are we? Ann Clin Microbiol Antimicrob. 2013;12:22.
19. Ling LL, Schneider T, Peoples AJ, et al. A new antibiotic kills pathogens without detectable resistance. Nature. 2015;517(7535):455–459.
20. Marks LR, Clementi EA, Hakansson AP, et al. The human milk protein-lipid complex HAMLET sensitizes bacterial pathogens to traditional antimicrobial agents. PLoS One. 2012;7(8):e43514.
21. May M. Drug development:time for teamwork. Nature. 2014;509(7498):S4–5.
22. Renwick MJ, Brogan DM, Mossialos E. A systematic review and critical assessment of incentive strategies for discovery and development of novel antibiotics. J Antibiot (Tokyo). 2016;69(2):73–88.• Systematic review on incentives for new antibiotics. A comprehensive review.
23. Brown ED. Is the GAIN act a turning point in new antibiotic discovery? Can J Microbiol. 2013;59(3):153–156.
24. The Pew Charitable Trust. Antibiotics currently in clinical development. September 2015 cited 2016 Feb 22. Available from:http://www.pewtrusts.org/en/multimedia/data-visualizations/2014/antibiotics-currently-in-clinical-development
25. Casadevall A. Antibody-based therapies for emerging infectious diseases. Emerg Infect Dis. 1996;2(3):200–208.
26. Stern M, Herrmann R. Overview of monoclonal antibodies in cancer therapy:present and promise. Crit Rev Oncol Hematol. 2005;54(1):11–29.
27. Chan CE, Chan AHY, Hanson BJ, et al. The use of antibodies in the treatment of infectious diseases. Singapore Med J. 2009;50(7):663–672. quiz 673.
28. Ter Meulen J. Monoclonal antibodies in infectious diseases:clinical pipeline in 2011. Infect Dis Clin North Am. 2011;25(4):789–802.
29. Oleksiewicz MB, Nagy G, Nagy E. Anti-bacterial monoclonal antibodies:back to the future? Arch Biochem Biophys. 2012;526(2):124–131.
30. Berry JD, Gaudet RG. Antibodies in infectious diseases:polyclonals, monoclonals and niche biotechnology. N Biotechnol. 2011;28(5):489–501.
31. Worgall S. 40 years on:have we finally got a vaccine for Pseudomonas aeruginosa? Future Microbiol. 2012;7(12):1333–1335.
32. Czaplewski L, Bax R, Clokie M, et al. Alternatives to antibiotics-a pipeline portfolio review. Lancet Infect Dis. 2016;16(2):239–251.•• Nice review on alternative agents.
33. Rello J, Perez A. Precision medicine for the treatment of severe pneumonia in intensive care. Expert Rev Respir Med. 2016;10(3):297–316.•• How to apply Precision Medicine to infection management.
34. Lehar SM, Pillow T, Xu M, et al. Novel antibody-antibiotic conjugate eliminates intracellular S. aureus. Nature. 2015;527(7578):323–328.
35. Morrison C. Antibacterial antibodies gain traction. Nat Rev Drug Discov. 2015;14(11):737–738.
36. Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med. 2010;362(3):197–205.
37. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs:no ESKAPE! an update from the infectious diseases society of America. Clin Infect Dis. 2009;48(1):1–12.
38. Jansen KU, Girgenti DQ, Scully IL, et al. Vaccine review:“Staphyloccocus aureus vaccines:problems and prospects”. Vaccine. 2013;31(25):2723–2730.
39. Rouha H, Badarau A, Visram ZC, et al. Five birds, one stone:neutralization of alpha-hemolysin and 4 bi-component leukocidins of Staphylococcus aureus with a single human monoclonal antibody. MAbs. 2015;7(1):243–254.
40. Sulakvelidze A, Alavidze Z, Morris JG, Jr. Bacteriophage therapy. Antimicrob Agents Chemother. 2001;45(3):649–659.
41. Abedon ST, Kuhl SJ, Blasdel BG, et al. Phage treatment of human infections. Bacteriophage. 2011;1(2):66–85.
42. Reardon S. Phage therapy gets revitalized. Nature. 2014;510(7503):15–16.
43. Wittebole X, De Roock S, Opal SM. A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens. Virulence. 2014;5(1):226–235.
44. Knoll BM, Mylonakis E. Antibacterial bioagents based on principles of bacteriophage biology:an overview. Clin Infect Dis. 2014;58(4):528–534.
45. Jassim SA, Limoges RG. Natural solution to antibiotic resistance:bacteriophages ‘the living drugs’. World J Microbiol Biotechnol. 2014;30(8):2153–2170.
46. Chan BK, Abedon ST, Loc-Carrillo C. Phage cocktails and the future of phage therapy. Future Microbiol. 2013;8(6):769–783.
47. Bragg R, van der Westhuizen W, Lee J-Y, et al. Bacteriophages as potential treatment option for antibiotic resistant bacteria. Adv Exp Med Biol. 2014;807:97–110.
48. Miedzybrodzki R, Fortuna W, Weber-Dabrowska B, et al. Phage therapy of staphylococcal infections (including MRSA) may be less expensive than antibiotic treatment. Postepy Hig Med Dosw (Online). 2007;61:461–465.
49. Rhoads DD, Wolcott RD, Kuskowski MA, et al. Bacteriophage therapy of venous leg ulcers in humans:results of a phase I safety trial. J Wound Care. 2009;18(6):237-8, 240-3.
50. Wright A, Hawkins CH, Anggård EE, et al. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol. 2009;34(4):349–357.
51. Sarker SA, Sultana S, Reuteler G, et al. Oral phage therapy of acute bacterial diarrhea with two coliphage preparations:a randomized trial in children from Bangladesh. EBioMedicine. 2016;4:124–137.
52. Grimwood K, Kyd JM, Owen SJ, et al. Vaccination against respiratory Pseudomonas aeruginosa infection. Hum Vaccin Immunother. 2015;11(1):14–20.
53. Vincent JL. Vaccine development and passive immunization for Pseudomonas aeruginosa in critically ill patients:a clinical update. Future Microbiol. 2014;9(4):457–463.
54. Garcia-Quintanilla M, Pulido MR, Carretero-Ledesma M, et al. Vaccines for antibiotic-resistant bacteria:possibility or pipe dream? Trends Pharmacol Sci. 2016;37(2):143–152.
55. Fowler VG, Allen KB, Moreira ED, et al. Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery:a randomized trial. Jama. 2013;309(13):1368–1378.
56. Bezay N, Ayad A, Dubischar K, et al. Safety, immunogenicity and dose response of VLA84, a new vaccine candidate against Clostridium difficile, in healthy volunteers. Vaccine. 2016;34(23):2585–2592.
57. Lombardo E, van der Poll T, DelaRosa O, et al. Mesenchymal stem cells as a therapeutic tool to treat sepsis. World J Stem Cells. 2015;7(2):368–379.• Stem cells for sespis. A challenging approach.
58. Gonzalez-Juarbe N, Gilley RP, Hinojosa CA, et al. Pore-Forming Toxins Induce Macrophage Necroptosis during Acute Bacterial Pneumonia. PLoS Pathog. 2015;11(12):e1005337.
59. Los FC, Randis TM, Aroian RV, et al. Role of pore-forming toxins in bacterial infectious diseases. Microbiol Mol Biol Rev. 2013;77(2):173–207.
60. Azeredo Da Silveira S, Perez A. Liposomes as novel anti-infectives targeting bacterial virulence factors? Expert Rev Anti Infect Ther. 2015;13(5):531–533.
61. Henry BD, Neill DR, Becker KA, et al. Engineered liposomes sequester bacterial exotoxins and protect from severe invasive infections in mice. Nat Biotechnol. 2015;33(1):81–88.• Liposomes for Severe infections. A visionary article.
62. Baquero F, Coque TM, de la Cruz F. Ecology and evolution as targets:the need for novel eco-evo drugs and strategies to fight antibiotic resistance. Antimicrob Agents Chemother. 2011;55(8):3649–3660.• Eco Evo strategies discussed in deep.
63. Baquero F, Lanza VF, Cantón R, et al. Public health evolutionary biology of antimicrobial resistance:priorities for intervention. Evol Appl. 2015;8(3):223–239.• Expert document on priorities for intervention.